REG - Clean Power Hydrogen - Memorandum of Understanding with ABE GRUPPE GmbH

Clean Power HydrogenAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260427:nRSa8893Ba&default-theme=true

RNS Number : 8893B  Clean Power Hydrogen PLC  27 April 2026

Clean Power Hydrogen plc

("CPH2" or the "Company")

 

Memorandum of Understanding with BKW Infra Services Europa SE subsidiary ABE
GRUPPE GmbH for partnership exploring sale of 175MW of electrolyser capacity

 

 

Clean Power Hydrogen plc (AIM:CPH2) is the developer of market disrupting and
IP-protected Membrane-Free Electrolyser ("MFE") technology for the
co-production of high purity hydrogen and above medical-grade purity oxygen.
The Company has entered into a non-binding Memorandum of Understanding ("MoU")
with ABE GRUPPE GmbH ("ABE") a subsidiary of BKW Infra Services Europa SE
("BKW") to explore the sale and integration of CPH2's unique technology across
its market activities

ABE is an integrated service provider in the field of renewable energy and
energy infrastructure, covering the full value chain of energy projects. The
range of services extends from engineering services and project development,
through the implementation of grid and energy systems, to operations
management and servicing. This is complemented by the independent
certification of components and systems to ensure compliance with regulatory
and technical standards.

Listed on the SIX Swiss Exchange with a market capitalisation of approximately
£8 billion, parent company BKW AG has a 125-year history and 11,500
employees. It is one of the largest energy supply companies in Switzerland
with a leading market position in infrastructure services. The companies have
agreed to develop a partnership seeking the supply, installation,
commissioning and maintenance of 175MW of electrolysers over the next 10
years.

The companies will use their combined skills and capabilities in developing
opportunities across ABEs and BKWs markets for CPH2s patent protected
technology. They will seek commercial opportunities to deploy equipment,
installation and commissioning services along with long-term operational and
maintenance activities.

Together, the companies are targeting a diverse customer base, including
renewable energy producers looking to monetise curtailed wind or solar
capacity, and industries where hydrogen and oxygen can boost process
efficiency, such as wastewater treatment and semiconductor fabrication.  It
will also include sectors such as life sciences, healthcare and mobility for
essential operations and data centres for long duration back-up storage and
dispatch.

The announcement supports Germany's National Hydrogen Strategy, which sets out
the Federal Government's ambition to accelerate the use of climate‑friendly
hydrogen technologies. The strategy targets the deployment of up to 10GW of
domestic green hydrogen production capacity by 2030, supported by significant
investment in electrolysers and hydrogen infrastructure.

Commenting on the agreement, Chief Executive Officer of CPH2, Jon Duffy, said:
"Together with ABE, BKW is a leading energy and infrastructure group with a
significant footprint across Germany and Switzerland. This agreement
reinforces the scalability and market appetite for the brand-new category of
electrolyser we have developed.  Our membrane-free technology offers a lower
lifetime cost for producing hydrogen and above medical grade oxygen.  We are
pleased to be partnering with ABE and BKW to demonstrate how our electrolysers
can deliver benefits across their project portfolio, and we look forward to
working with them and their end-user customers."

Daniel Lorenzen, General Manager BKW Renewable Energies and Managing Director
ABE Gruppe GmbH added: "This exciting partnership builds upon CPH2s existing
breakthrough 1MW membrane-free unit and expands over time with the forthcoming
5MW unit. With this technology we can offer our customers a more reliable,
higher purity, lower lifetime cost of hydrogen and oxygen production for the
growing decentralised energy market."

 

ENDS

Enquiries:

 

 Clean Power Hydrogen                                            +44 1302 328075

 Jon Duffy, Chief Executive Officer

 James Hobson, Chief Financial Officer

 Cavendish Capital Markets Limited - NOMAD & Joint Broker

 Neil McDonald                                                   +44 131 220 9771

 Peter Lynch                                                     +44 131 220 9772

 Hanna Leijonmarck

 Turner Pope Investments (TPI) Limited - Joint Broker

 Andy Thacker                                                    +44 203 657 0050

 Guy McDougall

 

Background on CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited which has
a decade of dedicated research and product development experience that has
delivered global patents in breakthrough hydrogen and oxygen production
technology. The Group's strategic objective is to deliver the lowest lifetime
Levelised Cost of Hydrogen ("LCoH") in the market in relation to the
production of hydrogen for the growing decentralised markets, which include
wastewater treatment, curtailed wind power capture, data centre backup,
medical and life sciences, and heavy-duty mobility applications. CPH2 is
listed on the AIM market and trades under the ticker AIM:CPH2.

 

For more information: https://www.cph2.com (https://www.cph2.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUGWCUPQGWC



            Copyright 2019 Regulatory News Service, all rights reserved